Efficacy of Vonoprazan-Based Triple Therapy with Sitafloxacin and Amoxicillin for Third-Line Helicobacter pylori Eradication: A Multicenter Prospective Analysis on Drug Resistance and gyrA Mutations
Digestive Diseases · 2025
DOI: 10.1159/000546914 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Digestive Diseases, 2025. Verfasst von Shunpei Wasaki und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Amoxicillin, Anti-Bacterial Agents, DNA Gyrase, Drug Resistance, Bacterial. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Abstract (Originalsprache)
Introduction
Vonoprazan (VPZ) is a potent gastric acid secretion inhibitor used to improve the outcomes of Helicobacter pylori (H. pylori) eradication treatments. However, the increasing prevalence of antibiotic-resistant H. pylori strains has limited the efficacy of H. pylori eradication therapies. The aim of this study was to evaluate the efficacy and safety of a 7-day triple therapy with VPZ, amoxicillin (AMOX), and sitafloxacin (STFX) as a third-line H. pylori eradication treatment.
Methods
Patients in whom second-line eradication therapy failed were enrolled. The minimum inhibitory concentrations of STFX and AMOX, as well as the gyrA mutation status of H. pylori strains, were determined before treatment. The patients received VPZ (20 mg) twice daily, AMOX (500 mg) four times daily, and STFX (100 mg) twice daily for 7 days (vonoprazan-amoxicillin-sitafloxacin [VAS] group). Successful eradication was evaluated using the 13C-urea breath test.
Results
Of the 114 patients enrolled, 75 were treated with the VAS regimen. The overall eradication rate in the VAS group was 90.7% and 94.4% in the intention-to-treat and per-protocol populations, respectively. The VAS regimen completely eradicated gyrA mutation-negative H. pylori strains. Furthermore, it eradicated all strains containing gyrA mutations at position D91. Adverse events were observed in 38.7% of patients, and treatment was discontinued in 1 patient because of eruption, diarrhea, and headache.
Conclusion
Overall, the 7-day VAS regimen exhibited an excellent safety profile and efficacy as a third-line eradication treatment, even against gyrA mutation-positive H. pylori strains.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
- Department of Gastroenterology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
- Division of Pharmacotherapeutics, Keio University Faculty of Pharmacy, Tokyo, Japan.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan.
- Department of Gastroenterology, Saitama Medical University Hospital, Saitama, Japan.
- Department of Gastroenterology, Nippon Koukan Hospital, Kawasaki, Japan.
Zitieren
APA
Wasaki, S., Mori, H., Matsuzaki, J., Suzuki, H., Hirata, K., Imaeda, H., Yoshioka, M., Nakazawa, A., Okazawa, A., Kanai, T., & Masaoka, T. (2025). Efficacy of Vonoprazan-Based Triple Therapy with Sitafloxacin and Amoxicillin for Third-Line Helicobacter pylori Eradication: A Multicenter Prospective Analysis on Drug Resistance and gyrA Mutations. Digestive Diseases. https://doi.org/10.1159/000546914
Vancouver
Wasaki S, Mori H, Matsuzaki J, Suzuki H, Hirata K, Imaeda H, et al. Efficacy of Vonoprazan-Based Triple Therapy with Sitafloxacin and Amoxicillin for Third-Line Helicobacter pylori Eradication: A Multicenter Prospective Analysis on Drug Resistance and gyrA Mutations. Digestive Diseases. 2025. doi:10.1159/000546914
BibTeX
@article{Wasaki2025,
author = {Wasaki, Shunpei and Mori, Hideki and Matsuzaki, Juntaro and Suzuki, Hidekazu and Hirata, Kenro and Imaeda, Hiroyuki and Yoshioka, Masahiro and Nakazawa, Atsushi and Okazawa, Akira and Kanai, Takanori and Masaoka, Tatsuhiro},
title = {Efficacy of Vonoprazan-Based Triple Therapy with Sitafloxacin and Amoxicillin for Third-Line Helicobacter pylori Eradication: A Multicenter Prospective Analysis on Drug Resistance and gyrA Mutations},
journal = {Digestive Diseases},
year = {2025},
doi = {10.1159/000546914}
}
EUVIMED